TEL AVIV, Israel, Nov. 12, 2025 — Corundum Neuroscience (CNS), the neuroscience venture builder and fund announced today they have participated in a Series A funding round for NextSense, a leader in wearable EEG technology helping consumers optimize brain health and sleep through Smartbuds. The investment will support NextSense’s next phase of growth as it prepares to bring its clinically-accurate in-ear EEG earbuds to market in Q4 2025.

“We are always looking for cutting-edge neuroscience solutions that improve brain health, making NextSense a perfect addition to our portfolio,” said Itsik Francis, PhD, Managing Partner, Business Development at Corundum Neuroscience. “We are excited to support the NextSense team to bring clinical-grade EEG monitoring to consumers, enabling them to better understand and improve their sleep.”

NextSense’s Smartbuds aim to deliver accurate sleep tracking while helping users unlock deeper, more restorative rest through auditory stimulation shown to boost slow-wave sleep by as much as 50% among early users. The buds use clinical-grade EEG technology to assess sleep stage and depth empowering users to better understand their sleep.

“We’re excited to partner with Corundum Neuroscience as we continue our work to democratize brain health. Their proven experience working with innovative neuroscience companies makes them an invaluable partner in launching Smartbuds to consumers everywhere,” said Jonathan Berent, Founder & CEO of NextSense.

About Corundum Neuroscience 

Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track-record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people’s health, longevity and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023, and is headquartered in Herzliya, Israel.

For company updates and information, follow Corundum Neuroscience on LinkedIn or visit: https://cnsfund.com. 

About NextSense

Based in Mountain View, CA, NextSense is redefining consumer wellness with the world’s first EEG earbuds. After years of research and clinical validation, the company created Smartbuds: a comfortable, everyday wearable that helps people sleep better, focus longer, and recharge more effectively. NextSense combines neuroscience and design to make brain health simple, accessible, and actionable.

Media Contact:  

Daniel Davis
FINN Partners for Corundum
[email protected]  

SOURCE Corundum Neuroscience

Arrived’s new rental property marketplace lets investors buy and sell shares of homes across the U.S., bringing stock market–style liquidity and flexibility to real estate investing

SEATTLE, Nov. 12, 2025 — Arrived, the leading platform for fractional real estate investing, today announced $27 million in new funding alongside the launch of the Arrived Secondary Market — a first-of-its-kind marketplace that enables investors to buy and sell shares of individual rental homes across the U.S. with just a few clicks.

This dual milestone marks a defining moment for both Arrived and the broader real estate industry, transforming real estate from a slow, offline transaction into a modern online experience — with tools for browsing, investing, and now trading shares of homes in just minutes.

More than 850,000 investors have joined Arrived, investing over $300 million in real estate assets spanning over 550 properties in 65 cities nationwide. In the first 3 weeks of trading, Arrived has seen investors place 57,000+ buy and sell orders.

These early results underscore how investors are actively using the platform to capture appreciation, rebalance portfolios, and access liquidity — behaviors that mirror the sophistication and efficiency of public markets.

“I love the audacity of the Arrived vision: a stock market for real estate,” said Ali Partovi, co-founder of Code.org and managing director of Neo, which has also backed Kalshi, Cursor, and Ramp. “I’m betting on them to democratize and digitize access to America’s $50 trillion in residential real estate.”

The new funding was led by Neo, with participation from Forerunner Ventures, Bezos Expeditions, Core, and additional strategic and community investments, bringing total new capital to $27 million and total funding to more than $60 million to date. Other existing investors include Marc Benioff, Spencer Rascoff, and Dara Khosrowshahi.

“We believe real estate investing is going to move online,” said Ryan Frazier, Co-Founder and CEO of Arrived. “Our vision is a future where real estate investing feels just like investing in public companies — where anyone can buy and sell shares of properties in minutes, not months.”

Through its peer-to-peer matching system, Arrived’s Secondary Market allows investors to:

• Buy and sell shares of rental properties directly from other real estate investors
• Exit or expand positions with greater flexibility—often in just minutes
• Capture appreciation and rebalance portfolios
• Access transparent pricing and seamless digital transactions

With investments starting at just $100, Arrived makes it possible for anyone to invest in real estate, earn passive income, and access potential appreciation without the hassles of traditional property management.

About Arrived
Arrived turns real estate into a modern, tradable asset. Think of it as the stock market for rental properties — where investors can buy shares in homes, earn rental income, and now sell those shares through the new Secondary Market.

Arrived is supported by world-class investors, including Neo, Bezos Expeditions, Marc Benioff, the founders of Warby Parker, Harry’s, and Allbirds, and Spencer Rascoff, former CEO of Zillow.  Learn more at Arrived.com

SOURCE Arrived

Led by New Enterprise Associates and Town Hall Ventures, new funding will enable company to expand to more specialties and continue its R&D investment in the industry’s first AI-enabled pharmacy management system

SAN FRANCISCO, Nov. 12, 2025 — House Rx, a health tech company focused on making specialty medications more accessible and affordable for patients, today announced it has raised $55 million in Series B equity and debt to expand its in-clinic specialty pharmacy model. The financing was led by New Enterprise Associates (NEA) and Town Hall Ventures and included participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. This new investment brings the company’s total capital raised to date to $100 million.

At a time when regulators and states are actively challenging the Pharmacy Benefit Manager (PBM)-owned, closed network specialty pharmacy model, House Rx offers an alternative vision – a nationwide network of locally owned, brick-and-mortar specialty dispensaries embedded in specialty clinics. The model puts patients and providers at the center and delivers vastly superior quality outcomes. By partnering with specialty clinics to integrate pharmacy services directly into care delivery, House Rx enables providers to offer high-touch, local alternatives to centralized pharmacy fulfillment models. This approach improves coordination between providers and pharmacists, reduces administrative complexity, and delivers better outcomes for patients dealing with complex conditions.

“There’s finally momentum behind creating a specialty pharmacy system that makes it easier for patients to seamlessly and more affordably access the medications they desperately need,” said Ogi Kavazovic, CEO & Founder of House Rx. “We’re seeing interest from stakeholders across the healthcare system — healthcare providers, manufacturers, payers, investors, and certainly employees who all recognize the opportunity to finally challenge the status quo in specialty pharmacy. We all want to do better by patients and help bring down the overwhelming expense to our healthcare system. With the support of this funding, we’re ready to scale operations to meet the exploding demand.”

To date, House Rx has partnered with more than 1,000 providers at 80 clinic sites nationwide, helping them stand up and successfully operate in-house pharmacies that deliver better outcomes for patients. House Rx processes approximately $1.5 billion in specialty scripts per year, with that volume expected to increase to $3 billion by the end of 2026.

“Specialty pharmacy is one of the highest-cost and least-transparent segments in healthcare and one that’s long overdue for change for the betterment of our healthcare system,” said Blake Wu, Partner at NEA. “NEA’s history of investing within specialty pharmacy and working with industry leaders in the category provides unique insight into its challenges, and we believe House Rx has an incredibly exciting vision to make a lasting change in this industry. The House Rx team is top notch, with a unique combination of specialty pharmacists and software builders working together to bring a new technology and service offering to market, making it cost effective for clinics to deliver complex specialty pharmacy services to their patients. We believe this model has the potential to change the landscape of specialty pharmacy for years to come.”

House Rx is the pharmacy management system of record for medically integrated dispensaries or pharmacies, and it comes with natively-embedded AI workflows. The tech platform is essential to driving the efficiencies and economies of scale required to succeed in this new model of local, decentralized pharmacy care. In April, House Rx announced their “Smart PA” AI feature, making prior authorizations in pharmacy 80% automated. The company is currently investing in several more AI capabilities which will come natively as part of its pharmacy management system.

“The House Rx platform blends software with clinical services, so patients start life-saving treatments in days, not weeks. With the need for improved patient access and adherence to medications, solutions like House Rx have never been more urgent,” said David Whelan, Co-Founder and General Partner at Town Hall Ventures. “We’re thrilled to support Ogi and his team of repeat healthcare and technology entrepreneurs in their mission to put providers and patients back in the center of the specialty pharmacy experience.”

About House Rx
House Rx  is a technology-enabled pharmacy services company focused on making specialty medication more accessible and affordable. The company helps clinics dispense specialty medications to their patients in a medically-integrated way using pharmacist expertise and modern technology. By helping physicians and pharmacists collaborate on patient care, House Rx is able to improve patient outcomes, lower the cost of care, and create a better experience for patients and their caregivers. Founded in 2021, House Rx is approaching 250 employees and was recently recognized by Time Magazine as one of the World’s Top HealthTech Companies of 2025.

About NEA
New Enterprise Associates, Inc.  (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of June 30, 2023 and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions.

About Town Hall Ventures
Started in 2018 by former Optum Group Executive Vice President and head of the Centers for Medicare and Medicaid Services and Senior White House Advisor Andy Slavitt and long-time investor and company-builder David Whelan, Town Hall Ventures invests in companies that transform access and equitable care for underserved Americans. Its aim is to deliver top-quartile financial results by finding and scaling models that improve outcomes in communities left behind by the United States healthcare system. To date, Town Hall has started or invested in 42 companies, with 8 of the first 16 investments valued at over $1 billion.

Contact: [email protected]  

SOURCE House Rx

BOSTON, Nov. 12, 2025 — Modulight Biotherapeutics, developer of novel optogenetic platform for the treatment of neurological disorders, announced today the closing of its Seed funding round raising $12.2 million. The Seed round was led by Jibe Ventures and LocalGlobe, with participation from Nexus Neurotech Ventures, RedSeed VC, Secret Chord Ventures, Fresh Fund, Saras Capital, SilverArc Capital and Sha’ar Mivnim. The funding will enable the Company to accelerate the development of its optogenetic technology platform and advance its therapeutic product pipeline towards the clinic.

“This funding marks a significant milestone for Modulight Biotherapeutics as we advance our mission to develop light-based therapeutics for the treatments of severe neurological diseases,” said Yotam Eldar, MD, CEO, Modulight Biotherapeutics. “We welcome our partners and investors, underscoring their collective confidence in Modulight’s vision, strategy and innovative solution. The financial round will allow us to enhance the preclinical development of our optogenetic switch for the treatment of trigeminal pain and initiate IND-enabling studies, manufacturing and discussions with the FDA.”

“The brain is extraordinarily complex and we cannot continue to treat it nonspecifically. This investment validates our unique approach to performing precise circuit-based neuromodulation of the neural pathways underlying different neurological conditions. We’ve already seen very promising efficacy in multiple animal models of neurological disorders including pain, epilepsy, and movement disorders such as Parkinson’s disease and essential tremor. We believe our proprietary technology and therapeutic pipeline have the potential to transform the treatment of neurological disorders,” added Dr. Eldar.

“We are excited to invest in Modulight Biotherapeutics’ financing round,” said John Propst, PhD, MBA, Principal at Nexus NeuroTech Ventures. “At Nexus, we invest in breakthrough technologies at the intersection of neuroscience and engineering that have the potential to transform patient care. Modulight’s optogenetic neuromodulation platform represents a fundamentally new way to target neural circuits with cell-type and pathway-level precision—something long sought but until now technically out of reach. We believe the company’s scientific foundation, executional excellence, and vision position it to redefine how we treat neurological and neuropsychiatric disorders driven by neuronal hyperexcitability. We’re proud to support this exceptional team as they pioneer a new therapeutic modality in brain health.”

About Modulight Biotherapeutics Optogenetics Platform

Modulight Biotherapeutics develops cutting-edge technologies for precise, targeted treatment of neurological disorders by addressing dysfunctional neuronal activity exactly where and when it occurs.

Today’s treatments for neurological disorders – such as drugs, surgery, or electrical stimulation – act broadly, often affecting large brain regions or brain networks indiscriminately. Yet the brain is far from uniform: it is a complex network of more than 86 billion neurons organized into distinct circuits and pathways.

Our optogenetic technology represents a fundamental leap. By enabling selective expression of light-sensitive proteins (called opsins) in specific neurons, we can modulate their activity with light—targeting the right neurons, in the right place, at the right time. This allows us to precisely rebalance hyperexcited brain networks that drive debilitating disorders such as severe chronic pain, epilepsy, and movement disorders—all without damaging surrounding tissue or interfering with healthy brain function.

Our therapeutic platform is based on eOPN3¹, a proprietary, hypersensitive, and biostable inhibitory opsin designed for clinical use. eOPN3 exerts a robust inhibitory effect at the presynaptic terminal, enabling pathway-specific neuromodulation. This versatile therapeutic platform is being developed for a range of neurological diseases. Our early preclinical studies show that eOPN3-based treatment has high efficacy in multiple animal models of pain, epilepsy, and movement disorders. As proof of concept, eOPN3 is initially being investigated for the treatment of trigeminal pain, a severe and often drug-resistant facial pain disorder. For this indication, eOPN3 can be delivered directly into the trigeminal ganglion through a simple, outpatient procedure.

About Modulight Biotherapeutics

Modulight Biotherapeutics is pioneering a new era of medicine for people living with neurological disorders – one that is fast-acting, precise, and designed to provide real relief without side effects. The Company’s platform uses a unique approach for modulating neuronal activity using light-activated proteins that are specifically targeted to pathological cells and neural pathways. Modulight’s therapeutic platform is based on technology licensed from YEDA, the commercial arm of the Weizmann Institute of Science. For more information, please visit https://www.modulight.bio/

Media Contact: 

Tsipi Haitovsky
Global Media Liaison
+972-525-989892
[email protected]

¹ Mahn M. et al. Efficient optogenetic silencing of neurotransmitter release with a mosquito rhodopsin. Neuron, Volume 109, Issue 10, 1621 – 1635.e8

SOURCE Modulight Biotherapeutics

NEW YORK, Nov. 12, 2025 — Lucky Energy, one of the fastest-growing energy beverage brands in the U.S., announced today that it has successfully closed an oversubscribed $25 million Series B funding round, led by Paine Schwartz Partners. The round also saw continued support from existing investors, along with new backers including North Fifth Services, LLC, Sequel, and Joyance Partners, among others.

This investment highlights growing investor confidence in the rapidly expanding clean-energy beverage market, one of the fastest-growing segments in the $100 billion energy drink industry.

This new funding will fuel Lucky Energy’s nationwide growth, including expanding its retail presence, strengthening national and regional partnerships, increasing marketing efforts, and expanding its team as it continues to scale to meet rising consumer demand. The company also welcomed two Paine Schwartz Partners Operating Directors to its Board of Directors: James Brennan, founder and CEO of ENlightened Brand Ventures, and Bob DeBorde, Chairman of Suja Life and Promix Nutrition, bringing decades of experience building category leaders. With longtime board member Dan Ginsberg, former CEO of Red Bull North America, they form a best-in-class leadership team driving Lucky Energy’s expansion.

Founded with the mission to create energy drinks that are cleaner, simpler, and healthier, Lucky Energy offers a refreshing, functional energy drink made with just five ingredients- containing 0 sugar, 0 calories, and no artificial additives. The brand has quickly become a favorite among consumers seeking sustained, feel-good energy without the crash.

This funding follows the viral sellout launch of Lucky Energy’s Black Label line, available exclusively on its website. Building on the momentum of its award-winning flavors, the brand has seen breakout growth in 2025. It is now available in over 15,000 retail locations nationwide, with plans to expand into Walmart, Sheetz, and Cumberland Farms stores across the country in December. With sales on track to double year-over-year, Lucky Energy is poised to bring its clean energy mission to even more consumers.

“Lucky Energy is redefining what consumers expect from energy drinks,” said Bob DeBorde. “By combining great taste with clean, functional ingredients, the brand is positioned to lead the next wave of growth in the category.”

“Every now and again, a brand has an incredible story to tell. We, at Paine Schwartz Partners, think Richard’s and the story behind Lucky is one of the greatest of all time,” said James Brennan.

“Lucky Energy was born from two core beliefs: that people deserve a cleaner, simpler energy drink they can feel genuinely good about and that life is too short not to go all in on your biggest dreams. James Brennan launched Suja around the same time I started Kate Farms, and both brands went on to achieve extraordinary success. To now partner with James, along with Bob DeBorde, whose experience as SVP of US Sales & Operations at Coca-Cola and CEO of Suja brings unmatched expertise, is a full-circle moment and an incredible honor. Lucky Energy is one of the fastest-growing beverage brands in America, and we’re just getting started. We’re building a modern energy powerhouse, and our ambition is as bold as the people who drink Lucky,” said Richard Laver, Founder & CEO, Lucky Energy.

For more information, visit LuckyBevCo.com, check the store locator, and follow @LuckyEnergyOfficial on Instagram and @LuckyEnergy on TikTok.

About Lucky Energy
Lucky Energy is a simpler, better-for-you energy drink for those who believe success is built, not found. Founded by serial beverage visionary Richard Laver, Lucky Energy elevates performance with clean ingredients, bold natural flavor, and 33% fewer ingredients than traditional energy drinks. Each can is powered by a proprietary blend of 5 super-ingredients, including maca and beta-alanine, formulated to sharpen focus, boost endurance, and sustain drive. With 0 sugar, 0 calories, and 0 artificial additives, Lucky Energy fuels the athletes, creators, and everyday achievers who make their own luck—one intentional move at a time.

Lucky Energy is available online at LuckyBevCo.com, TikTok Shops, Amazon, and in more than 15,000 retail locations nationwide, including leading retailers in the Boston area such as Shaw’s and Star Market.

For press inquiries, please contact Valeria Carrasco directly at [email protected]

SOURCE Lucky Beverage Company

Investment fuels global expansion and AI-powered platform development for strategic sourcing and supply chain intelligence solutions serving hospitals and health systems

VERO BEACH, Fla., Nov. 12, 2025 — Meperia, the premier healthcare procurement intelligence and strategic sourcing platform, today announced a strategic growth investment from Diversis Capital, a leading lower middle market technology investment firm with $3 billion in assets under management.

The investment accelerates Meperia’s expansion across the United States, United Kingdom, and Ireland while advancing AI-powered analytics and predictive capabilities to transform how hospitals make procurement decisions and manage product data.

Meperia serves leading health systems including Northside Hospital, Valleywise Health, and Allegheny Health Network, delivering proven solutions that normalize product data, optimize sourcing decisions, and provide real-time market intelligence, addressing critical challenges in cost reduction, contract optimization, and data integrity.

Transforming Healthcare Procurement

The investment comes as hospitals struggle with fragmented product data, inconsistent pricing information, and manual sourcing processes that result in millions in unnecessary spending and missed savings opportunities.

“This partnership with Diversis Capital marks a transformative milestone,” said Tom Frith, President of Meperia. “Healthcare organizations face mounting challenges with fragmented product data and opaque pricing that cost millions annually. With Diversis’s operational expertise and growth capital, we’re accelerating our ability to deliver data normalization and procurement intelligence to hospitals globally.”

Platform Capabilities

The investment will enhance AI-powered capabilities across Meperia’s proven platform modules:

• The Library: AI-enabled content management generating universal product information across categories
• Virtual Item Master (VIM): Millions of targeted products, fully attributed and normalized
• Content Manager: Data normalization providing single source of uniform product data
• Implant Management Solution: Automated “Bill Only” and “Bill & Replace” processes
• Contract Management: Outsourced contract acquisition and processing services
• Market Intelligence: AI and Power BI analytics for pricing data and sourcing decisions
• FDA Recall Integration: Real-time alerts preventing purchases of recalled products

Pam Pulit, Director, Supply Chain System & Master Data Management at Allegheny Health Network highlighted the impact of Meperia’s platform: “Clean data is the bedrock of a modern supply chain. By normalizing and attributing every item, we created the visibility needed to manage spend, reduce risk, and stay proactive—not reactive.”

“Meperia has built the procurement intelligence platform that solves healthcare’s long-standing purchasing challenges,” said Ron Nayot, Managing Partner at Diversis Capital. “They’ve proven that clean data and AI-driven insights can transform hospital purchasing decisions. We’re investing to scale this critical capability globally.”

About Meperia
Meperia is the first supply chain content enabler to bring predictive intelligence solutions to the healthcare market. Our proprietary artificial intelligence imitates the ease of consumer on-line shopping. Meperia’s SaaS-based solution puts controls and real-time visibility around an organization’s spend at the point of requisitioning to ensure every purchase is on contract, on price and on target to their product formulary goals—before users buy! As visionaries, our industry firsts include data normalization, content management solutions, and our new implant management solution. Learn more atwww.meperia.com.

About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.

Contact: Chris Tofalli
Chris Tofalli Public Relations, LLC
914-834-4334
[email protected]

SOURCE Meperia

Series C led by global consortium values company at $2 billion, accelerates product and customer expansion as demand grows for faster, more efficient data center inference

SANTA CLARA, Calif., Nov. 12, 2025 — d-Matrix, the pioneer in generative AI inference compute for data centers, has closed $275 million in Series C funding, valuing the company at $2 billion and bringing the total raised to date to $450 million. The new capital will advance the company’s roadmap, accelerate global expansion and support multiple large-scale deployments of the world’s highest performing, most efficient data center inference platform for hyperscale, enterprise, and sovereign customers.

The oversubscribed round attracted leading investment firms across Europe, North America, Asia, and the Middle East. The funding is co-led by a global consortium including BullhoundCapital, Triatomic Capital, and Temasek. The round also includes new participation from the Qatar Investment Authority (QIA) and EDBI, alongside follow-on participation from M12, Microsoft’s Venture Fund, as well as Nautilus Venture Partners, Industry Ventures, and Mirae Asset.

d-Matrix’s full-stack inference platform combines breakthrough compute-memory integration, high-speed networking, and inference-optimized software to deliver 10× faster performance, 3× lower cost, and 3–5× better energy efficiency than GPU-based systems. Solutions powered by d-Matrix’s Corsair™ inference accelerators, JetStream™ NICs and Aviator™ software can produce up to 30K tokens per second at 2ms per token on a Llama 70B model. The platform’s compute-dense design allows customers to run up to 100B-parameter models incredibly fast in a single rack.

This step-change in performance and efficiency directly addresses growing AI sustainability challenges. By enabling one data center to handle the workload of ten, d-Matrix offers a clear path to reducing global data center energy consumption while enabling enterprises to deliver cost-efficient, profitable AI services without compromise.

“From day one, d-Matrix has been uniquely focused on inference. When we started d-Matrix six years ago, training was seen as AI’s biggest challenge, but we knew that a new set of challenges would be coming soon,” said Sid Sheth, CEO and co-founder of d-Matrix. “We predicted that when trained models needed to run continuously at scale, the infrastructure wouldn’t be ready. We’ve spent the last six years building the solution: a fundamentally new architecture that enables AI to operate everywhere, all the time. This funding validates that vision as the industry enters the Age of AI Inference.”

Investor confidence reflects d-Matrix’s differentiated technology, rapid customer growth, and expanding network of global partners — including the recently announced d-Matrix SquadRack™ open standards-based reference architecture with Arista, Broadcom, and Supermicro. A strong product roadmap featuring 3D memory-stacking innovations and a customer-centric go-to-market strategy further establishes d-Matrix as a cornerstone of the new AI infrastructure stack.

Investor Voices
“As the AI industry’s focus shifts from training to large-scale inference, the winners will be those who anticipated this transition early and built for it,” said Per Roman, Founder of BullhoundCapital. “d-Matrix stands out not only for its technical depth but for its clear strategic vision. The team understood before anyone else that inference would define the economics of AI — and they’re executing brilliantly on that insight.”

“AI inference is becoming the dominant cost in production AI systems, and d-Matrix has cracked the code on delivering both performance and sustainable economics at scale,” said Jeff Huber, General Partner at Triatomic Capital. “Their digital in-memory compute architecture is purpose-built for low-latency, high-throughput inference workloads that matter most. With Sid, Sudeep, and their world-class team, plus an exceptional ecosystem of partners, d-Matrix is redefining what’s economically possible in AI infrastructure.”

“The explosion in AI inference demand shows us that efficiency and scalability can be key contributors to revenue capture and profitability for hyperscalers and AI factories,” said Michael Stewart, Managing Partner at M12, Microsoft’s Venture Fund. “d-Matrix is the first AI chip startup to address contemporary unit economics in LLM inference for models of a range of sizes that are growing the fastest, with differentiated elements in the in-memory product architecture that will sustain the TCO benefits with leading latency and throughput.”

Morgan Stanley served as the exclusive placement agent, and Wilson Sonsini Goodrich & Rosati served as legal counsel to d-Matrix.

Key Facts

• Founded: 2019 | HQ: Santa Clara, CA
• Global Offices: Toronto (Canada); Sydney (Australia); Bangalore (India); Belgrade (Serbia)
• Founders: Sid Sheth (CEO), Sudeep Bhoja (CTO)
• Core Products: Corsair inference accelerators, JetStream networking accelerators, Aviator software stack
• Employees: 250+ worldwide
• Series C Funding: $275 million | Total Funding: $450 million | Valuation: $2B

About d-Matrix
d-Matrix is pioneering accelerated computing for AI inference, breaking through the limits of latency, cost and energy. Its Corsair accelerators, JetStream networking, and Aviator software deliver fast, sustainable AI inference at data center scale.

The terms d-Matrix, JetStream, Corsair and Aviator are trademarks and/or registered trademarks of d-Matrix, Inc. in the U.S. and other countries. All rights reserved.

SOURCE d-Matrix

VILNIUS, Lithuania, Nov. 12, 2025 — Global health and wellness company Kilo Health rebrands to Kilo. The move reflects its expansion into new business opportunities in longevity, anti-ageing, beauty, and personal development. It also demonstrates Kilo’s growing focus on co-founding, venture building and early-stage startup investments.

Founded in 2013, Kilo Health has grown from a local wellness startup into a global healthtech force, building a wide range of solutions – from digital apps to physical products – that have reached over 10 million consumers worldwide.

In 2022, Kilo Health was named Europe’s second fastest-growing tech company by the Financial Times. Now, the company is bringing its expertise in building and scaling ventures to other founders. Kilo’s current portfolio includes nine strong ventures, including Bioma, Pulsetto, Go Health, Ratepunk, and others.

Rebranding to Kilo marks the company’s evolution into a highly valued co-founding partner for entrepreneurs building new, exciting businesses in health, wellness, beauty and personal development.

“Kilo has expanded from one product to over 30. Now, it’s time to share that experience with the next generation of builders,” says Žygimantas Surintas, CEO of Kilo. “Our goal is to empower entrepreneurs with both funding and the operational power to move fast and make an impact.”

A Partner for High-Velocity Growth

Kilo provides ambitious entrepreneurs with hands-on support from the MVP stage, enabling them to build, test and scale innovative ideas together at exceptional speed. The company will partner with builders primarily in health and wellness, while also exploring other high-potential industries.

Kilo’s initial investment tickets range from €50,000 to €1 million, with follow-on funding reaching up to €10 million. To date, the company has invested over €10 million in external startups and nearly twice that amount in its own R&D and product development.

These efforts are powered by Kiloverse – Kilo’s internal ecosystem, which provides the infrastructure and knowledge: access to marketing expertise, technology tools, and global partnerships; experience in direct-to-consumer product business models and experts in R&D, nutrition, research, and others.

Kilo Health, now – Kilo, has demonstrated exceptional business growth, doubling its revenues over the past five years to surpass €233 million this year. In the next three years, Kilo plans to invest an additional €20 million in AI development and reach almost €9 billion in revenue.

Headquartered in Vilnius, Lithuania, Kilo employs over 500 people globally.

More information: kilo.co, plus – photos.

SOURCE Kilo

By connecting directly to a business inbox, EVE turns everyday communications into a real-time revenue engine – automating what traditional CRMs never could

SAN FRANCISCO, Nov. 11, 2025 — EVE, the first Inbox Revenue Engine for B2B small businesses, today announced it has raised $2 million in pre-seed funding led by Firsthand.VC, with participation from a16z’s Scout Fund, Acquisition.com Ventures, Geek Ventures, Founders Future, Punch Capital, Silicon Gardens and prominent angels, including co-founders of Slack and Hugging Face, and the former CEO of Oura. The funding will accelerate product development and support EVE’s rollout to hundreds of small businesses already on its waitlist – a first step toward scaling to thousands in the coming months.

EVE acts as an always-on Inbox Revenue Engine, connecting directly to email and calendar to track and manage real-time revenue activity – automatically identifying new opportunities, surfacing forgotten leads, and drafting context-aware follow-ups. By eliminating the need for manual CRM updates or workflow changes, EVE helps small businesses recover 20–30% of potential revenue lost in day-to-day communication gaps.

“CRMs were built for people who have time for managing them. Small businesses don’t have time for all of this, starting with manual data entry,” said Vadim Rogovskiy, CEO and co-founder of EVE. “EVE lives inside email and calendar and does the work for you autonomously, turning everyday conversations into a single live revenue machine where nothing gets lost.”

“Building on the idea of revenue intelligence, EVE adds autonomous execution and visibility. It doesn’t just tell teams what to do; it helps them do it – learning from every connected inbox to build a single live dashboard of all revenue activity across the company – making it easy to see what’s moving, what’s stalled, and what’s being missed.”

While in stealth, over 500 small businesses joined EVE’s waitlist, with some of them already turning their inboxes into live revenue dashboards.

“I didn’t realize how much revenue was buried in our inbox until EVE started identifying it and helping us to close it,” said Josh Hess, VP of Business Development at Leadature, one of EVE’s first customers. “In just three months, we closed 25% more deals with the same team and no workflow changes.”

The idea for EVE emerged after hundreds of interviews with SMB owners, revealing that up to 80% of their work happens over email –yet most of that intelligence never makes it into CRMs or project management tools. Before founding EVE, Rogovskiy was building an AI-driven roll-up of small businesses, acquiring and modernizing operations with AI agents. “That journey exposed how much value was being lost inside inboxes,” said Rogovskiy. “EVE is the AI Inbox Revenue Engine designed to fix that.”

“I back people first, and Vadim has shown exceptional clarity in navigating this market,” said Simon Chan, General Partner at Firsthand.VC, and a four-time founder whose own company was acquired by Salesforce. “Having helped build Salesforce’s Einstein platform, I can say EVE is reimagining CRM from the ground up – bringing automation and intelligence to the businesses that need it most.”

EVE is built for industries where email volume directly equals revenue potential – including consulting, construction, distribution, recruiting, brokerage, and event management. The platform integrates seamlessly with Gmail and Outlook, requires no setup or training, and starts delivering insights within minutes. Future releases will expand into multi-channel lead tracking, upsell detection, and churn prediction, bringing small businesses a step closer to a fully autonomous revenue engine

About EVE

EVE is the first Inbox Revenue Engine for small businesses. By integrating with email, documents, and calendars, EVE continuously identifies overlooked leads, stalled deals, and buying signals – helping companies unlock 20–30% of hidden revenue without changing how they work. Co-founded by Vadim Rogovskiy, serial entrepreneur and founding partner at Rebel Capital, EVE is building the default revenue operating system for the next generation of SMBs.

Logo: https://mma.prnewswire.com/media/2818775/EVE_Logo.jpg

SOURCE EVE